Around the world, the fight for affordable medical treatment is intensifying. Headline-grabbing battles are being waged in India, where the Chennai High Court recently decided a major constitutional case over access to lifesaving cancer medication. In Thailand, Abbott Laboratories, a multinational pharmaceutical giant, has withdrawn registration of all its new medicines as leverage in a prolonged battle with the government over drug prices and patent recognition.
Noted: And in Thailand, at least one of the drugs that Abbott is withholding, Zemplar (paricalcitol), is based on a patent licensed out of the University of Wisconsin at Madison.